Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
59651-0180-90 59651-0180 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Jan. 11, 2019 In Use
64980-0404-03 64980-0404 Toremifene Citrate Toremifene Citrate 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 18, 2019 In Use
70121-1654-01 70121-1654 Triamcinolone Acetonide Triamcinolone Acetonide 200.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1651-01 70121-1651 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1651-05 70121-1651 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1652-01 70121-1652 Triamcinolone Acetonide Triamcinolone Acetonide 200.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1653-01 70121-1653 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1655-01 70121-1655 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1657-01 70121-1657 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
70121-1657-05 70121-1657 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Dec. 11, 2017 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59572-0720-12 59572-0720 Fedratinib Hydrochloride Inrebic 100.0 mg/1 Chemotherapy Enzyme Inhibitor JAK2, FLT3 Oral Aug. 16, 2019 In Use
68727-0712-01 68727-0712 Lurbinectedin ZEPZELCA 0.5 mg/mL Chemotherapy Alkylating Agent Adduct Forming Agent Intravenous June 15, 2020 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous June 10, 2019 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous April 23, 2020 In Use
59572-0711-01 59572-0711 Luspatercept REBLOZYL 25.0 mg/1 Ancillary Therapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
59572-0775-01 59572-0775 Luspatercept Reblozyl 75.0 mg/1 Immunotherapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
72607-0100-00 72607-0100 tazemetostat TAZVERIK 200.0 mg/1 Chemotherapy Enzyme Inhibitor EZH2 Oral Jan. 23, 2020 In Use
73535-0208-01 73535-0208 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug. 5, 2020 In Use
00069-0305-01 00069-0305 Trastuzumab-qyyp Trazimera 420.0 mg/20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 24, 2020 In Use
55513-0132-01 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 11, 2019 In Use
00069-0284-03 00069-0284 Palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
65162-0240-03 65162-0240 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 29, 2018 In Use
00054-9817-25 00054-9817 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9817-29 00054-9817 PredniSONE PredniSONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9818-25 00054-9818 PredniSONE PredniSONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9818-29 00054-9818 PredniSONE PredniSONE 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9828-25 00054-9828 PredniSONE PredniSONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00054-9828-31 00054-9828 PredniSONE PredniSONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 23, 2020 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00378-0014-01 00378-0014 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 18, 1992 In Use
00555-0572-02 00555-0572 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 1, 1990 In Use
00555-0572-35 00555-0572 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 1, 1990 In Use
00143-9830-01 00143-9830 Methotrexate Methotrexate 1.0 g/1 Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous April 25, 2017 In Use
00703-4239-01 00703-4239 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 23, 2014 In Use
00703-4239-81 00703-4239 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 19, 2016 In Use
00703-4244-01 00703-4244 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 4, 2006 In Use
00703-4244-81 00703-4244 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 15, 2016 In Use
00703-4246-01 00703-4246 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 1, 2006 In Use
00703-4246-81 00703-4246 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 25, 2015 In Use
57277-0105-05 57277-0105 carboplatin Injection Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
57277-0106-15 57277-0106 carboplatin Injection Carboplatin 150.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
00078-0681-66 00078-0681 Dabrafenib Tafinlar 75.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 1, 2016 In Use
00078-0682-66 00078-0682 Dabrafenib Tafinlar 50.0 mg/1 Chemotherapy Enzyme Inhibitor BRAF Oral April 12, 2016 In Use
00069-3030-20 00069-3030 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 In Use
00069-3034-20 00069-3034 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 In Use
00310-0482-30 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 13, 2015 In Use
00409-0181-01 00409-0181 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 26, 2011 In Use
00409-0181-25 00409-0181 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 9, 2013 In Use
00409-0182-01 00409-0182 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 22, 2011 In Use
00409-0182-25 00409-0182 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 29, 2013 In Use
00409-0183-01 00409-0183 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 24, 2011 In Use
00409-0183-25 00409-0183 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 9, 2013 In Use
00409-0185-01 00409-0185 GEMCITABINE Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 26, 2011 In Use
00409-0187-01 00409-0187 GEMCITABINE GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Nov. 15, 2010 In Use
25021-0234-10 25021-0234 Gemcitabine Hydrochloride gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
55111-0686-07 55111-0686 Gemcitabine gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
55111-0687-25 55111-0687 Gemcitabine gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
00378-2245-77 00378-2245 imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
00378-2246-93 00378-2246 imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
00310-0679-12 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-60 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-95 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 31, 2017 In Use
68083-0176-01 68083-0176 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 6, 2017 In Use
68083-0177-01 68083-0177 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 6, 2017 In Use
16729-0049-53 16729-0049 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 7, 2017 In Use
16729-0049-54 16729-0049 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 13, 2017 In Use
54569-6124-02 54569-6124 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 9, 2016 In Use
54569-6208-00 54569-6208 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 10, 2016 In Use
54569-6208-01 54569-6208 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 10, 2016 In Use
54569-6208-02 54569-6208 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 10, 2016 In Use
54868-5749-00 54868-5749 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 16, 2007 In Use
54868-5749-01 54868-5749 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 16, 2007 In Use
54868-5887-00 54868-5887 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 8, 2008 In Use
54868-5887-01 54868-5887 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 8, 2008 In Use
54868-5888-00 54868-5888 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 8, 2008 In Use
55045-3848-09 55045-3848 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 27, 2007 In Use
55154-3680-00 55154-3680 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 27, 2007 In Use
55154-3683-00 55154-3683 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 27, 2007 In Use
55154-5369-00 55154-5369 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 5, 2012 In Use
55154-5431-00 55154-5431 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 31, 2007 In Use
57237-0077-10 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0077-30 57237-0077 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0078-10 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57237-0078-30 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
57881-0444-01 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0444-10 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-01 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-10 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
60760-0305-10 60760-0305 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 23, 2014 In Use
60760-0306-10 60760-0306 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 1, 2016 In Use
61919-0218-10 61919-0218 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2014 In Use
62756-0240-64 62756-0240 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 2, 2007 In Use

Found 10,000 results in 5 milliseconds — Export these results